Track 13 of 14
Cardiovascular Genomics & Precision Medicine
Polygenic risk, FH, gene editing (VERVE-102) and clonal hematopoiesis.
Genomic cardiology is becoming clinically actionable. The track covers VERVE-102 base-editing of PCSK9 in heterozygous FH (HEART-2), NTLA-2001 CRISPR for ATTR, MYBPC3 AAV gene therapy for HCM, and RP-A501 for Danon disease. Sessions examine polygenic risk scores validated across diverse ancestries, cascade screening operational models for FH, ACMG variant interpretation in inherited arrhythmias, and clonal hematopoiesis (CHIP) as an emerging modifier of HF, AS, and post-MI outcomes. Lamin A/C and titin-truncating dilated cardiomyopathy management is increasingly genotype-driven.
Focus areas
- VERVE-102 PCSK9 base editing and CRISPR cardiology
- Familial hypercholesterolemia: cascade screening models
- ATTR-CM: NTLA-2001 CRISPR and silencer therapy
- Polygenic risk scores: ancestry-aware ASCVD prediction
- Clonal hematopoiesis (CHIP) as a CV risk modifier
- Inherited arrhythmias: ACMG variant interpretation
- DCM genotype-driven management: titin, lamin A/C, Danon